Ventyx Biosciences Inc (VTYX) PT Raised to $60 at Jefferies

Ventyx Biosciences (VTYX) Shares Surge, Key Overhang Removed Says Analyst

Shares of Ventyx Biosciences (NASDAQ: VTYX) are up significantly Monday (up 62.5% at the time of writing), with analysts pointing to the approval of Bristol Myers Squibb's (NYSE: BMY) deucravacitinib on Friday night.

Jefferies analyst Michael Yee reiterated a Buy rating and raised the firm's price target on the stock to $60 from $30 in a note reacting to the news. Yee explained that "VTYX has the potentially cleanest oral TYK2 inhibitor. The first one from BMY has just been approved, importantly with a very clean label... More

Evercore on Ventyx Biosciences (VTYX): 'Certainly expecting a strong move on Monday'

Evercore analyst Josh Schimmer comments on Ventyx Biosciences (NASDAQ: VTYX) "We got the much-anticipated deucrava label with no black box warning - rather language noting its unclear if TYK2 will carry JAK risks which makes sense. This has been a top incoming query with... More

Credit Suisse Keeps $60 PT on Ventyx Biosciences Inc (VTYX), 'deucravacitinib’s clean label sets a highly favorable precedent for the TYK2i class'

Credit Suisse analyst Tiago Fauth reiterated an Outperform rating and $63.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX).

The analyst comments "Bristols Deucravacitinib Approved in Psoriasis (PsO): Friday, deucravacitinib was approved by the FDA for the treatment of moderate-to-severe psoriasis, making it the first approved... More

Piper Sandler Keeps $50 PT on Ventyx Biosciences Inc (VTYX), 'we believe that the read through to VTYX will support a rally the shares tomorrow'

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $50.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX).

The analyst comments "No black box warning opens the door to broader inflammatory franchise for VTYX - here is why. Given the clean label from FDA, we believe that the read through to VTYX will support a rally the shares tomorrow, and we would expect the positive... More

Stifel Comments on Ventyx Biosciences Inc (VTYX) Following Deucravacitinib Approval

Stifel analyst Alex Thompson reiterated a Buy rating and $45.00 price target on Ventyx Biosciences Inc (NASDAQ: VTYX).

The analyst comments "The approval of BMY's deucravacitinib (Sotyktu) with no JAK-like black box (label) represents a near best case for the next-gen TYK2 space (VTYX, Nimbus, Alumis, others), as we believe consensus (and our base case) largely anticipated... More

UPDATE: Ventyx Biosciences Inc (VTYX) PT Raised to $65 at Oppenheimer

(Updated - September 12, 2022 8:12 AM EDT)

Oppenheimer analyst Jeff Jones raised the price target on Ventyx Biosciences Inc (NASDAQ: VTYX) to $65.00 (from $40.00) while maintaining a Outperform rating.

The analyst comments "Late Friday BMY announced the approval of deucravacitinib-SotyktuTM (Press Release). Key... More

Ventyx Biosciences (VTYX) Climbs 44%

Ventyx Biosciences (NASDAQ: VTYX) Climbs 44%